tiprankstipranks
Trending News
More News >
Ajinomoto Co Inc (ADR) (AJINY)
OTHER OTC:AJINY

Ajinomoto Co (AJINY) AI Stock Analysis

Compare
21 Followers

Top Page

AJINY

Ajinomoto Co

(OTC:AJINY)

Select Model
Select Model
Select Model
Neutral 62 (OpenAI - 5.2)
Rating:62Neutral
Price Target:
$33.00
▲(57.97% Upside)
Action:ReiteratedDate:02/08/26
The score is held back primarily by rich valuation (high P/E with a modest yield). Financial performance is steady overall—good revenue and gross margin trends, moderate leverage, and positive free cash flow—but weaker cash conversion and some net margin pressure reduce confidence. Technically, the trend is positive, yet overbought momentum indicators suggest higher near-term downside risk.
Positive Factors
Diversified business lines and global footprint
Ajinomoto's multi-segment model (food products plus amino acids and bio-based businesses) and established international presence reduce single-market dependency. Structural diversification supports steady revenue streams and resilience to regional demand shocks over the medium term.
Revenue growth with improving gross margin
Sustained TTM revenue growth paired with a modest but persistent gross margin increase indicates durable pricing power, favorable mix, or cost control. Those levers support medium-term operating cash generation and competitiveness in packaged foods and ingredient markets.
Solid balance sheet and sizeable equity base
Moderate leverage and a substantial equity cushion provide financial flexibility for capex, R&D, and M&A. This structural balance-sheet strength helps the company absorb shocks, fund strategic initiatives, and maintain investment-grade operational capacity over a multi-quarter horizon.
Negative Factors
Net margin compression
A decline in net margin versus prior years signals pressure below the operating line—potentially rising SG&A, financing costs, or lower non-operating gains. Persisting margin compression would weaken return on capital and restrict reinvestment capacity over several quarters.
Mixed cash conversion and modest OCF/sales
Free cash flow covering just over half of net income and modest operating cash relative to sales point to working-capital swings or timing issues. Structural cash-conversion inconsistency can limit debt reduction, dividends, or growth investments across multiple reporting periods.
Upward shift in leverage vs FY2023
An observable rise in leverage compared with FY2023 reduces the margin of financial safety. If debt levels remain elevated, interest exposure and reduced flexibility could constrain strategic spending or increase refinancing risk over the medium term.

Ajinomoto Co (AJINY) vs. SPDR S&P 500 ETF (SPY)

Ajinomoto Co Business Overview & Revenue Model

Company DescriptionAjinomoto Co., Inc. engages in the seasonings and foods, frozen foods, and healthcare and other businesses in Japan and internationally. Its Seasonings and Foods segment offers sauces and seasonings products under the AJI-NO-MOTO, HON-DASHI, Cook Do, Ajinomoto KK Consommé, Pure Select Mayonnaise, Ros Dee, Masako, Aji-ngon, Sazón, Sajiku, and CRISPY FRY names; and solutions and ingredients to consumer foods and food service industries. This segment also provides instant noodles under the Knorr Cup Soup, and YumYum names; coffee under the Birdy and Blendy brands; powdered drink under the Birdy 3in1 name; MAXIM products; Chyotto Zeitakuna Kohiten products; and gift sets and office supplies comprising coffee vending machines, tea server, etc. The Frozen Foods segment offers Chinese dumplings, cooked rice, noodles, desserts, shumai, processed chicken, and other products. The Healthcare and Other segment provides amino acids to various industries, such as pharmaceuticals, foods, and cosmetics; sports nutrition products; personal care ingredients; and sterile products, as well as engages in the provision of contract manufacturing services for pharmaceutical intermediates and active ingredients. This segment also offers Ajinomoto Build-up Film, an interlayer insulating material for semiconductor packages. Ajinomoto Co., Inc. was founded in 1909 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyAjinomoto generates revenue through multiple key streams, primarily from its food products and amino acid segments. The food products division contributes significantly through the sale of seasonings, sauces, and frozen foods, catering to both retail and food service markets. The amino acids segment earns income by supplying essential amino acids and other bio-based products to pharmaceutical and cosmetic industries, as well as to animal feed manufacturers. Additionally, Ajinomoto's partnerships with various food manufacturers and distributors enhance its market reach and facilitate joint product development. The company also invests in research and development to innovate and expand its product offerings, which contributes to sustaining its revenue growth. International operations further diversify its income sources, as the company has established a strong presence in North America, Europe, and Asia.

Ajinomoto Co Earnings Call Summary

Earnings Call Date:May 07, 2026
(Q4-2025)
|
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted record sales and profits, strong performance in overseas markets, and positive shareholder returns. However, these positives were offset by challenges in the Japan Frozen Foods segment, impacts from structural reforms, and shipment delays in the Bio-Pharma Services. Despite the lowlights, the overall outlook for FY 2025 remains optimistic, with significant growth expected in key business areas.
Q4-2025 Updates
Positive Updates
Record Sales and Business Profit
Ajinomoto achieved new records in both sales and business profits for FY 2024, with sales reaching JPY 1.530 trillion, a 6% increase year-on-year, and business profit hitting JPY 159.3 billion, a 7.9% increase year-on-year.
Strong Overseas Performance
The Seasonings & Foods segment overseas continued to perform well, contributing significantly to the overall revenue increase.
Bio-Pharma Services & Ingredients Growth
Ajinomoto projects significant profit growth in the Bio-Pharma Services & Ingredients segment for FY 2025, driven by strong demand in Europe and AJICAP royalty income.
Positive Shareholder Returns
Ajinomoto announced a JPY 100 billion share repurchase program and plans to increase annual dividends by JPY 8 to JPY 48 in FY 2025.
Functional Materials Outlook
The Functional Materials business expects double-digit growth in FY 2025 due to favorable market conditions, particularly in semiconductors and AI-related demand.
Negative Updates
Profit Decrease in Certain Segments
Profit attributable to owners of the parent company decreased significantly due to structural reform expenses and impairment losses related to the sale of subsidiaries and plants.
Challenges in Japan's Frozen Foods Segment
The Frozen Foods segment struggled in Japan due to high raw material costs and adverse foreign exchange impacts, resulting in decreased profit.
Impacts of Structural Reforms
The sale of Althea and structural reform expenses negatively impacted the Healthcare and Others segment, causing a decrease in ROE and ROIC.
Delays in Bio-Pharma Services Shipments
There was a delay in shipments within the Bio-Pharma Services, affecting business profit projections.
Company Guidance
The Ajinomoto earnings call provided comprehensive guidance for the fiscal year 2025, highlighting significant metrics and strategic initiatives. Sales and business profit for FY 2024 reached unprecedented levels, with sales at JPY 1.530 trillion, a 6% increase year-on-year, and business profit at JPY 159.3 billion, a 7.9% rise. Despite structural reform expenses impacting profit attributable to owners, the FY 2025 forecast projects further growth, with sales expected to reach JPY 1.618 trillion, a 5.7% increase, and business profit anticipated to hit JPY 180 billion, a 13% rise. The company plans to enhance shareholder returns by increasing dividends and repurchasing shares. Additionally, Ajinomoto aims to achieve a 19% ROE, excluding the Forge acquisition impact, surpassing its initial target. The call also outlined strategic focus areas, including premium product launches and operational improvements in frozen foods, along with a significant increase in profit from Bio-Pharma Services and Ingredients.

Ajinomoto Co Financial Statement Overview

Summary
Income statement strength (78) from strong TTM revenue growth and slightly better gross margin is tempered by net margin compression versus prior years. Balance sheet is solid (72) with moderate leverage, though leverage has risen versus FY2023. Cash flow is the main drag (63) due to mixed cash conversion (FCF only a bit over half of net income) despite positive OCF/FCF.
Income Statement
78
Positive
TTM (Trailing-Twelve-Months) revenue is up strongly versus the last annual period, and gross margin has improved (about 37% TTM vs ~36% in FY2025), showing decent pricing/mix and cost control. However, profitability is mid-single-digit, with net margin around 5% TTM and below the ~6–7% level seen in FY2022–FY2024, indicating some recent margin pressure despite stable operating margin near ~8%.
Balance Sheet
72
Positive
Leverage is moderate with debt running at roughly 0.6x equity in both TTM (Trailing-Twelve-Months) and the latest annual report, and equity remains substantial relative to the asset base. The main watch-out is the upward shift in leverage versus FY2023 (when debt-to-equity was notably lower), while returns on equity are solid but not accelerating (roughly ~10–11% recently).
Cash Flow
63
Positive
Cash generation is positive with TTM (Trailing-Twelve-Months) operating cash flow and free cash flow both solidly positive, and free cash flow growth close to flat year-over-year. That said, cash conversion is somewhat mixed: free cash flow covers only a bit more than half of net income in TTM, and operating cash flow relative to sales is modest, suggesting working-capital or cash-timing swings that can dampen consistency.
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.56T1.53T1.44T1.36T1.15T1.07T
Gross Profit579.58B550.76B511.45B470.39B425.90B406.22B
EBITDA207.71B209.22B219.41B202.42B188.15B168.89B
Net Income78.61B70.27B87.12B94.06B75.72B59.42B
Balance Sheet
Total Assets1.90T1.72T1.77T1.51T1.46T1.43T
Cash, Cash Equivalents and Short-Term Investments201.98B182.77B194.19B145.09B169.26B193.69B
Total Debt447.24B455.35B491.68B288.56B313.91B350.42B
Total Liabilities1.08T907.86B890.43B688.77B717.32B763.44B
Stockholders Equity744.06B746.80B814.69B768.68B686.91B620.26B
Cash Flow
Free Cash Flow129.75B114.81B96.05B44.59B64.86B79.61B
Operating Cash Flow229.65B209.90B168.07B117.64B145.58B165.65B
Investing Cash Flow-79.63B-77.38B-132.43B-30.09B-61.57B-66.25B
Financing Cash Flow-183.63B-137.68B-6.75B-111.06B-123.06B-60.39B

Ajinomoto Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price20.89
Price Trends
50DMA
23.95
Positive
100DMA
24.74
Positive
200DMA
25.66
Positive
Market Momentum
MACD
2.15
Negative
RSI
80.17
Negative
STOCH
94.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AJINY, the sentiment is Positive. The current price of 20.89 is below the 20-day moving average (MA) of 27.34, below the 50-day MA of 23.95, and below the 200-day MA of 25.66, indicating a bullish trend. The MACD of 2.15 indicates Negative momentum. The RSI at 80.17 is Negative, neither overbought nor oversold. The STOCH value of 94.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AJINY.

Ajinomoto Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$24.24B9.8127.29%5.19%-5.65%0.41%
68
Neutral
$14.19B29.706.02%4.82%1.55%-40.81%
65
Neutral
$18.78B23.8914.32%2.61%1.64%-1.83%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
62
Neutral
$29.32B56.2710.61%1.11%2.69%-17.14%
61
Neutral
$11.67B-17.44%4.45%-0.66%-326.55%
54
Neutral
$29.33B-4.97-12.87%6.75%-3.70%-431.05%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AJINY
Ajinomoto Co
31.82
11.90
59.71%
GIS
General Mills
45.23
-12.50
-21.65%
HRL
Hormel Foods
25.60
-1.79
-6.54%
SJM
JM Smucker
115.95
9.70
9.13%
MKC
McCormick & Company
71.04
-9.46
-11.76%
KHC
Kraft Heinz
24.61
-4.37
-15.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 08, 2026